Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
复制标题
DOI：
10.3390/cancers14030482
复制
发表时间：
2022-01-18
期刊：
影响因子：
5.2
通讯作者：
Machado HL
中科院分区：
文献类型：
--
作者：
Newton EE;Mueller LE;Treadwell SM;Morris CA;Machado HL
三阴性乳腺癌（TNBC）是最具侵袭性的乳腺癌亚型之一，主要是由于异质性和缺乏治疗选择。由于缺乏靶向激素受体的表达，化疗是目前TNBC的标准治疗方法。然而，化疗和放疗后的复发和转移仍然是死亡率的主要原因。为了开发更有效的TNBC治疗方法，参与肿瘤生长、血管形成和细胞凋亡的分子途径已被研究作为潜在的靶点。在这篇综述中，我们概述了可能涉及未来TNBC治疗的有希望的生物学靶点。三阴性乳腺癌（TNBC）是一种高度侵袭性的乳腺癌。由于其异质性和缺乏激素受体表达，这种亚型比其他形式的乳腺癌更容易转移和抵抗治疗。由于缺乏靶向受体，化疗和保乳手术一直是患者的主要治疗选择。然而，化疗耐药和肿瘤局部复发是常见的。新兴的免疫疗法已经开始改变被诊断为TNBC的患者的治疗计划。在这篇综述中，我们讨论了在TNBC中发现的各种免疫途径，以及它们作为新的潜在治疗选择的靶点所起的作用。各种抑制细胞生长周期关键通路、DNA修复机制、上皮间充质转化和免疫抑制的治疗方案已被证明可提高该疾病患者的生存率。到目前为止，有希望的结果，继续研究免疫治疗和新辅助治疗选择TNBC可能会改变这些诊断的治疗过程在未来。
Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes, largely due to heterogeneity and lack of treatment options. Due to absence of targetable hormone receptor expression, chemotherapy is the current standard of care for TNBC. However, recurrence and metastasis following treatment with chemotherapy and radiation remain major contributors to mortality. To develop more effective treatments of TNBC, molecular pathways involved in tumor growth, vascularization, and apoptosis have been investigated as potential targets. In this review, we outline promising biological targets that may be implicated in future TNBC treatments. Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Due to its heterogeneity and lack of hormone receptor expression, this subtype is more likely to metastasize and resist treatment attempts than are other forms of breast cancer. Due to the absence of targetable receptors, chemotherapy and breast conserving surgery have been the predominant treatment options for patients. However, resistance to chemotherapy and local recurrence of the tumors is frequent. Emerging immunotherapies have begun to change treatment plans for patients diagnosed with TNBC. In this review, we discuss the various immune pathways identified in TNBC and the role they play as targets for new potential treatment choices. Various therapeutic options that inhibit key pathways in cellular growth cycles, DNA repair mechanisms, epithelial mesenchymal transition, and immunosuppression have been shown to improve survival in patients with this disease. With promising results thus far, continued studies of immunotherapy and neoadjuvant therapy options for TNBC are likely to alter the treatment course for these diagnoses in the future.
登录
查看更多内容
影响因子：
45.3
作者：
Bardia, Aditya;Mayer, Ingrid A.;Vahdat, Linda T.
通讯作者：
Vahdat, Linda T.
Wnt-β-catenin途径在三阴性乳腺癌中的差异激活以PTEN依赖性方式增加了MMP7。
影响因子：
3.7
作者：
Dey N;Young B;Abramovitz M;Bouzyk M;Barwick B;De P;Leyland-Jones B
通讯作者：
Leyland-Jones B
影响因子：
--
作者：
Bergin, Alice R T;Loi, Sherene
通讯作者：
Loi, Sherene
影响因子：
9.7
作者：
Ahmed, Kamal;Koval, Alexey;Katanaev, Vladimir L.
通讯作者：
Katanaev, Vladimir L.
影响因子：
4.6
作者：
El Guerrab, Abderrahim;Bamdad, Mahchid;Aubel, Corinne
通讯作者：
Aubel, Corinne